Blunt Rochester continued to push for transparency regarding the scientific foundation of the vaccine advice discussed within the administration. She asked Overton specifically whether she had reviewed scientific data regarding the feasibility and safety of splitting the Measles, Mumps, and Rubella (MMR) vaccine into separate doses, or whether she had evaluated claims regarding whether current vaccine doses were the size of a soda bottle.
Throughout the additional line of questioning, Overton again dodged the specific inquiries, declining to detail what specific data had been reviewed or to clarify the origins of the unusual claims regarding vaccine dosage sizes.
Flavored vapes
The hearing also brought renewed attention to leadership vacancies and regulatory shifts at the Food and Drug Administration (FDA). The FDA has been without a confirmed commissioner since May, when Dr. Marty Makary resigned from the position following reported tension with the White House over e-cigarette regulation. Makary stepped down after resisting administrative pressure to approve the sale of flavored e-cigarette and vape products.
Despite widespread, bipartisan opposition from health advocates and lawmakers who view flavored e-cigarettes as products designed and marketed primarily to attract youth, the FDA issued a policy directive in early May allowing their sale.
Sen. Chris Murphy (D-Conn.) presented a detailed timeline during the hearing, alleging a direct connection between political fundraising and the sudden policy reversal regarding flavored vapes.
Setting out the chronological order of events, Murphy detailed how the regulatory shift unfolded over the course of less than a week:
"On April 30th, it’s a Thursday afternoon, Reynolds, one of the biggest tobacco companies in the country, makes an $8 million donation to the president. Two days later on Saturday, because of that donation, they have lunch with the president and they tell him that they want a change in FDA rules, especially regarding flavored vapes. The president calls the FDA commissioner, he calls the secretary of [the health department], and three days later on Tuesday, new guidance is issued that paves the way to the sale of flavored vapes."
Following his detailed recap of the sequence of events, Murphy asked Overton directly whether she saw a clear correlation between the $8 million corporate donation and the rapid policy modification by regulatory officials. Murphy further pressed Overton on whether she believed such a rapid, donor-driven timeline represented how the FDA should properly operate when making decisions that impact public health and youth safety.
Overton rejected the senator’s premise and defended the administration’s integrity without addressing the specific dates, financial contributions, or meetings outlined in Murphy’s timeline.
"I reject the framing of that question," Overton replied, adding that Trump remains "committed to the best possible outcomes for American[s]."
The hearing concluded with key questions regarding FDA oversight, executive advisory standards, and public health communications remaining sharply contested between administration officials and congressional overseers.
